EUVIMEDEUVIMED entdecken
Crossref

EVA1A reverses lenvatinib resistance in hepatocellular carcinoma through regulating PI3K/AKT/p53 signaling axis

Xiaokun Liu, Xiao Gao, Yuling Yang, Di Yang, Qingming Guo, Lianhui Li, Shunlong Liu, Wanxin Cong, Sen Lu, Lin Hou, Bin Wang, Ning Li iD

Apoptosis · 2024-08 · 29 (7-8) · 1161-1184

DOI: 10.1007/s10495-024-01967-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Apoptosis, online erschienen am 14.05.2024. Verfasst von Xiaokun Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medicine, College of Electronic Information, Micro-Nano Technology College, Qingdao University, Qingdao, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Quinolines, Liver Neoplasms, Phenylurea Compounds. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 59 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularQuinolinesLiver NeoplasmsPhenylurea CompoundsDrug Resistance, NeoplasmTumor Suppressor Protein p53Phosphatidylinositol 3-KinasesSignal TransductionProto-Oncogene Proteins c-aktHumansAnimalsCell Line, TumorMiceApoptosisCell ProliferationMice, NudeAntineoplastic AgentsGene Expression Regulation, NeoplasticMaleXenograft Model Antitumor AssaysMice, Inbred BALB CProto-Oncogene Proteins c-mdm2Female

Stichwörter der Autor:innen

AKTAutophagyDrug resistanceEVA1AHepatocellular carcinomaLenvatinibMDM2p53

Substanzen

lenvatinibQuinolinesPhenylurea CompoundsTumor Suppressor Protein p53Phosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktAntineoplastic AgentsTP53 protein, humanProto-Oncogene Proteins c-mdm2

Autor:innen und Institutionen

  • School of Basic Medicine, College of Electronic Information, Micro-Nano Technology College, Qingdao University, Qingdao, China.
  • Department of Infectious Diseases, Affiliated Hospital of Qingdao University, Qingdao, China.
  • Clinical Laboratory, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, China.
  • Department of Clinical Medicine, Qingdao Medical College, Qingdao University, Qingdao, China.
  • Department of Medical Laboratory, Qingdao Medical College, Qingdao University, Qingdao, China.
  • School of Basic Medicine, College of Electronic Information, Micro-Nano Technology College, Qingdao University, Qingdao, China. ning-99@163.com.

ORCID-Profile: Ning Li

Zitieren

APA

Liu, X., Gao, X., Yang, Y., Yang, D., Guo, Q., Li, L., Liu, S., Cong, W., Lu, S., Hou, L., Wang, B., & Li, N. (2024). EVA1A reverses lenvatinib resistance in hepatocellular carcinoma through regulating PI3K/AKT/p53 signaling axis. Apoptosis, 29(7-8), 1161-1184. https://doi.org/10.1007/s10495-024-01967-0

Vancouver

Liu X, Gao X, Yang Y, Yang D, Guo Q, Li L, et al. EVA1A reverses lenvatinib resistance in hepatocellular carcinoma through regulating PI3K/AKT/p53 signaling axis. Apoptosis. 2024;29(7-8):1161-1184. doi:10.1007/s10495-024-01967-0

BibTeX
@article{Liu2024,
  author = {Liu, Xiaokun and Gao, Xiao and Yang, Yuling and Yang, Di and Guo, Qingming and Li, Lianhui and Liu, Shunlong and Cong, Wanxin and Lu, Sen and Hou, Lin and Wang, Bin and Li, Ning},
  title = {EVA1A reverses lenvatinib resistance in hepatocellular carcinoma through regulating PI3K/AKT/p53 signaling axis},
  journal = {Apoptosis},
  year = {2024},
  volume = {29},
  number = {7-8},
  pages = {1161--1184},
  doi = {10.1007/s10495-024-01967-0}
}
Kostenlos starten →